Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C

Equality Impact Assessment (Guidance development) (PDF 171 KB)

Final appraisal determination

Committee papers (PDF 3.07 MB)

Final appraisal determination document (PDF 581 KB)

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): appraisal consultation

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): appraisal consultation document (PDF 567 KB)

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): committee papers A information

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): committee papers A (PDF 7.45 MB)

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): committee papers B information

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): committee papers B (PDF 6.95 MB)

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): response to consultee and commentator comments on the draft scope and provisional matrix (PDF 265 KB)

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): final matrix (PDF 102 KB)

Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): final scope (PDF 112 KB)